Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term combination chemotherapy. Found 15 abstracts

Komaki R, Swann RS, Ettinger DS, Glisson BS, Sandler AB, Movsas B, Suh J, Byhardt RW. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. International Journal of Radiation Oncology Biology Physics. 2005 Jun;62(2):342-50.
Treat J. Incorporating novel agents with gemicitabine-based treatment of NSCLC. Lung Cancer. 2005 Oct;50:S8-S9.
Ibrahim D, Smith MR, Varterasian M, Karanes C, Millenson M, Yeslow G, Pemberton P, Lai P, Abrams J, Al-Katib A. Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma. Leukemia & lymphoma. 2004 Oct;45(10):2079-84.
Ozols RF. Chemotherapy for ovarian cancer: Beyond paclitaxel plus carboplatin. Cancer Journal from Scientific American. 1999 Nov;5(6):336-8.
Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clinical Cancer Research. 1998 May;4(5):1305-14.
Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: Primary and interval cytoreductive surgery. Seminars in Oncology. 1998 Jun;25(3):326-34.
Langer CJ. Chemotherapeutic inroads in treating stage IV non-small cell lung cancer. Current Problems in Cancer. 1996 Jul;20(4):221-46.
Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation therapy oncology group protocol 91-06. Journal of Clinical Oncology. 1996 Apr;14(4):1055-64.
Rosvold E. Chemoprevention of lung cancer. Current Problems in Cancer. 1996 Jul;20(4):266-71.
Langer CJ, Leighton J, McAleer C, Comis R, Odwyer P, Ozols R. Paclitaxel and Carboplatin in the Treatment of Advanced Nonsmall Cell Lung-Cancer. Seminars in Oncology. 1995 Jun;22(3):64-9.
Hogan WM, Boente MP. The Role of Surgery in the Management of Recurrent Gynecologic Cancer. Seminars in Oncology. 1993 Oct;20(5):462-72.
Schilder RJ, Ozols RF. New Therapies for Ovarian-Cancer. Cancer Investigation. 1992 Jan;10(4):307-15.
Young RC. Etoposide in the Treatment of Non-Hodgkins-Lymphomas. Seminars in Oncology. 1992 Dec;19(6):19-25.
Langer CJ, Nash S, Catalano R, Rosenblum NG, Hogan WM, Comis RL, Odwyer PJ. Phase-Ii Trial of Thio-Tepa in Relapsed and Refractory Ovarian- Carcinoma. Gynecologic Oncology. 1991 Dec;43(3):242-6.
Odwyer PJ, Langer CJ, Walczak J, Levy MH, Padavicshaller K, Hudes GR, Litwin S, Comis RL. Phase-Ii Study of Weekly 5-Fluorouracil, Cisplatin and Vinblastine in Advanced Non-Small-Cell Lung-Cancer. European Journal of Cancer. 1991 Dec;27(12):1589-93.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term combination chemotherapy

combination chemotherapy randomized trial carcinoma cisplatin survival phase-ii trial doxorubicin stage-iii gynecologic-oncology-group cyclophosphamide radiotherapy cancer randomized vp-16-213 cooperative-oncology-group phase-ii trial debulking surgery standard regimen chop dichlorodiammineplatinum(ii) cell quality-of-life hexamethylmelamine cisplatin-based chemotherapy 2nd-line therapy autologous blood cell-lines 1-hour infusion infusion cell lung-cancer lung cancer non-hodgkins-lymphoma vindesine irradiation metaanalysis combined chemoradiotherapy disease patients intestinal-obstruction small-bowel obstruction bone-marrow support regimens chemotherapy resistance series pelvic squamous-cell carcinoma therapy radiation- vitamin-e look laparotomy bronchial squamous metaplasia buthionine neck-cancer prevention gemcitabine bone-marrow transplantation relapsed Hodgkin lymphoma high-dose carboplatin multiple-drug platinum-resistant concurrent chemotherapy histiocytic lymphoma novel agents term follow-up sulfoximine first relapse beta- protein-kinase-c tumor xenografts elderly patients aggressive lymphomas supportive care stem-cell transplantation thoracic radiation therapy expression carotene non-small-cell lung cancer advanced ovarian-carcinoma multidrug-resistance gene cross-resistance 10-deaza-aminopterin folate smokers 2nd- intraperitoneal cisplatin disease taxol treatment high-dose therapy bronchogenic-carcinoma cis- etoposide small-cell lung cancer fluorouracil oncology-group adenocarcinoma p- analogs residual-disease poor-prognosis exenteration salvage therapy fractionation toxicity cyclophosphamide plus cisplatin surgical-management large-cell lymphoma radical hysterectomy glycoprotein cis-dichlorodiammineplatinum(ii) PEND head enhanced dna-repair prognostic factors bone-marrow-transplantation secondary cytoreductive surgery diffuse histiocytic lymphoma antitumor efficacy
Last updated on Wednesday, August 12, 2020